<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38777">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601573</url>
  </required_header>
  <id_info>
    <org_study_id>5172-083</org_study_id>
    <secondary_id>2015-003187-37</secondary_id>
    <nct_id>NCT02601573</nct_id>
  </id_info>
  <brief_title>Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection</brief_title>
  <official_title>A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-site, open-label trial of the co-administration of a fixed-dose
      combination (FDC) of elbasvir (50 mg)/grazoprevir (100 mg) (EBR/GZR) and 400 mg of
      sofosbuvir (SOF), with and without ribavirin (RBV), in treatment-na誰ve (TN) and
      treatment-experienced (TE) subjects with chronic Hepatitis C Virus (HCV) Genotype 3 (GT3)
      infection with compensated cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy)</measure>
    <time_frame>Up to 28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to 18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing from study therapy due to an AE</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR24 (Sustained Virologic Response 24 weeks after the end of all study therapy)</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>GZR 100 mg provided in a FDC tablet also containing EBR 50 mg (MK-5172A) taken q.d. by mouth in the morning.</description>
    <arm_group_label>Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks</arm_group_label>
    <arm_group_label>Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_label>Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks</arm_group_label>
    <arm_group_label>Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks</arm_group_label>
    <other_name>MK-5172A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir</intervention_name>
    <description>EBR 50 mg provided in a FDC tablet also containing GZR 100 mg (MK-5172A) taken q.d. by mouth in the morning.</description>
    <arm_group_label>Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks</arm_group_label>
    <arm_group_label>Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_label>Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks</arm_group_label>
    <arm_group_label>Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks</arm_group_label>
    <other_name>MK-5172A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose of 800 mg to 1400 mg based on participant body weight.</description>
    <arm_group_label>Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks</arm_group_label>
    <other_name>Rebetol速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>SOF 400 mg tablet taken q.d. by mouth in the morning with food.</description>
    <arm_group_label>Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks</arm_group_label>
    <arm_group_label>Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_label>Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks</arm_group_label>
    <arm_group_label>Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks</arm_group_label>
    <other_name>Sovaldi速, Harvoni速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has HCV RNA (&gt;= 10,000 IU/mL in peripheral blood) at screening

          -  has documented HCV GT3 (with no evidence of non-typeable or mixed GT infection)

          -  has compensated cirrhosis of the liver

          -  has liver imaging within 6 months of Day 1 with no evidence of hepatocellular
             carcinoma (HCC)

          -  is either HCV TN or TE (i.e., has documented prior virologic failure or intolerance
             to peg-interferon/ribavirin)

          -  is otherwise healthy as determined by medical history, physical examination,
             electrocardiogram (ECG), and clinical laboratory measurements

          -  has compensated cirrhosis of the liver

          -  is TN or TE (i.e., documented prior virologic failure or intolerance to
             peg-interferon/ribavirin)

          -  is not of reproductive potential, or agrees to not impregnate a partner or become
             pregnant for at least 2 weeks prior to the first dose of study drug, and for 7 months
             after the final dose of study drug (or longer if dictated by local regulations)

        Exclusion Criteria:

          -  has previously received one or more doses of a direct-acting antiviral (DAA)

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B (hepatitis B surface antigen [HBsAg] positive)

          -  has a recent (within 5 years) history of malignancy or is under evaluation for HCC or
             other suspected malignancy

          -  is currently or has participated (within past 30 days) in a study with an
             investigational compound

          -  has clinically-relevant drug or alcohol abuse within the past 12 months of screening

          -  is a female and is pregnant or breast-feeding

          -  is a male whose female partner is/are pregnant

          -  has any of the following:

          -  organ transplants

          -  poor venous access

          -  history of gastric surgery or malabsorption disorder

          -  current or history of clinically significant cardiac abnormalities or dysfunction

          -  chronic pulmonary disease

          -  hemoglobinopathy

          -  history of hospitalization within 3 months prior to enrollment

          -  medical or surgical condition that may result in need for hospitalization during the
             course of the study

          -  any condition requiring, or likely to require, chronic systemic administration of
             corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppresant
             drugs during the course of the study

          -  any condition, prestudy laboratory or ECG abnormality, or history of any illness,
             which could confound results of the study or pose additional risks in administering
             study drugs in the opinion of the investigator

          -  has a life-threatening serious AE (SAE) during the screening period

          -  has evidence of history of chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 24, 2017</lastchanged_date>
  <firstreceived_date>November 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
